Dalbavancin is thermally stable at clinically relevant temperatures against methicillin-sensitive Staphylococcus Aureus
-
Published:2023-06-28
Issue:3
Volume:8
Page:175-181
-
ISSN:2206-3552
-
Container-title:Journal of Bone and Joint Infection
-
language:en
-
Short-container-title:J. Bone Joint Infect.
Author:
Hoyt Aaron K.ORCID, Lawler Patrick, Bostrom Mathias, Carli Alberto V., Levack Ashley E.
Abstract
Abstract. Introduction: While the rate of orthopaedic infections has remained constant
over the years, the burden on healthcare systems continues to rise with an
aging population. Local antibiotic delivery via polymethyl methacrylate bone
cement is a common adjunct in treating bone and joint infections.
Dalbavancin is a novel lipoglycopeptide antibiotic in the same class as
vancomycin that has shown efficacy against Gram-positive organisms when used
systemically but has not been investigated as a local antibiotic. This study
aims to identify whether dalbavancin is thermally stable at the temperatures
expected during the polymerization of polymethyl methacrylate cement.
Methods: Stock solutions of dalbavancin were prepared and heated using a
polymerase chain reaction machine based upon previously defined models of
curing temperatures in two clinically relevant models: a 10 mm
polymethyl methacrylate bead and a polymethyl methacrylate articulating knee
spacer model. Aliquots of heated dalbavancin were then transferred to be
incubated at core body temperature (37 ∘C) and analyzed at various
time points up to 28 d. The minimum inhibitory concentration at which
90 % of colonies were inhibited (MIC90) for each heated sample was
determined against methicillin-sensitive Staphylococcus aureus (American Type Culture Collection, ATCC, 0173K) using a standard
microbroth dilution assay.
Results: The average MIC90 of dalbavancin was 1.63 µg mL−1
±0.49 against 0173K S. aureus. There were no significant differences in the
relative MIC90 values after heating dalbavancin in either model
compared to unheated control dalbavancin.
Conclusions: Dalbavancin is thermally stable at the curing temperatures of
polymethyl methacrylate cement and at human core body temperature over
28 d. Future in vitro and in vivo studies are warranted to further investigate the role
of dalbavancin as a local antibiotic prior to its clinical use.
Funder
Orthopedic Research and Education Foundation National Institute of Allergy and Infectious Diseases
Publisher
Copernicus GmbH
Subject
Infectious Diseases,Orthopedics and Sports Medicine,Surgery
Reference35 articles.
1. Almangour, T. A., Perry, G. K., Terriff, C. M., Alhifany, A. A., and Kaye,
K. S.: Dalbavancin for the management of gram-positive osteomyelitis:
Effectiveness and potential utility, Diagn. Microbiol. Infect. Dis., 93,
213–218, https://doi.org/10.1016/j.diagmicrobio.2018.10.007, 2019. 2. Appelbaum, P. C.: Reduced glycopeptide susceptibility in
methicillin-resistant Staphylococcus aureus (MRSA), Int. J. Antimicrob. Agents,
30, 398–408, https://doi.org/10.1016/j.ijantimicag.2007.07.011, 2007. 3. Berend, K. R., Lombardi Jr., A. V., Morris, M. J., Bergeson, A. G., Adams,
J. B., and Sneller, M. A.: Two-stage treatment of hip periprosthetic joint
infection is associated with a high rate of infection control but high
mortality, Clin. Orthop. Relat. Res., 471, 510–518, https://doi.org/10.1007/s11999-012-2595-x,
2013. 4. Biedenbach, D. J., Ross, J. E., Fritsche, T. R., Sader, H. S., and Jones, R.
N.: Activity of dalbavancin tested against Staphylococcus spp. and
beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse
medical centers in the United States, J. Clin. Microbiol., 45, 998–1004, https://doi.org/10.1128/JCM.02368-06, 2007. 5. Biedenbach, D. J., Bell, J. M., Sader, H. S., Turnidge, J. D., and Jones, R.
N.: Activities of dalbavancin against a worldwide collection of 81,673
gram-positive bacterial isolates, Antimicrob. Agents Chemother., 53,
1260–1263, https://doi.org/10.1128/AAC.01453-08, 2009.
|
|